Latest News and Press Releases

ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share...

On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!

Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.

Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.

Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.

Washington, DC, May 15, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating Congressional action that could lead to safer skies for travelers with potentially...

Washington, D.C., April 26, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) celebrates the signing of Elijah’s Law in Maryland. The legislation, passed by the Maryland...

Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Global Skin Allergy Testing Market" report has been added to ResearchAndMarkets.com's offering.The global market for skin allergy testing is expected...

New York , Feb. 21, 2024 (GLOBE NEWSWIRE) -- The global auto-injectors market size is predicted to expand at 17% CAGR between 2024 and 2036. The market is projected to garner a revenue of USD 33...

Washington, DC, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement which may be attributed to Kenneth Mendez, president and CEO:  ...